PhaseBio to Present at Cowen and Company 40th Annual Health Care Conference
February 26 2020 - 4:01PM
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a
clinical-stage biopharmaceutical company focused on the development
and commercialization of novel therapies for cardiopulmonary
diseases, today announced that Chief Executive Officer Jonathan P.
Mow will present a company overview at the Cowen and Company 40th
Annual Health Care Conference on Wednesday, March 4, at 10:40 a.m.
EST in Boston.
A live and archived version of the presentation
will be available on the company’s website at
https://investors.phasebio.com.
About PhaseBioPhaseBio
Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical
company focused on the development and commercialization of novel
therapies for cardiopulmonary diseases. The company’s pipeline
includes: PB2452, a novel reversal agent for the antiplatelet
therapy ticagrelor; PB1046, a once-weekly vasoactive intestinal
peptide receptor agonist for the treatment of pulmonary arterial
hypertension; and PB6440, an oral agent for the treatment of
resistant hypertension. PhaseBio’s proprietary elastin-like
polypeptide (ELP) technology platform enables the development of
therapies with potential for less-frequent dosing and improved
pharmacokinetics, including PB1046, and drives both internal and
partnership drug-development opportunities.
PhaseBio is located in Malvern,
PA and San Diego, CA. For more information, please
visit www.phasebio.com.
Investor Contact: John Sharp PhaseBio
Pharmaceuticals, Inc. Chief Financial Officer (610) 981-6506
john.sharp@phasebio.com
Media Contact:Jason SparkCanale
Communications(619) 849-6005jason@canalecomm.com
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From May 2024 to Jun 2024
PhaseBio Pharmaceuticals (NASDAQ:PHAS)
Historical Stock Chart
From Jun 2023 to Jun 2024